# **Summary of Product Characteristics**

#### **1 NAME OF THE MEDICINAL PRODUCT**

Zovirax 200 mg/5 mL Oral Suspension

## **2 QUALITATIVE AND QUANTITATIVE COMPOSITION**

Oral Suspension containing 200 mg aciclovir per 5 mL.

Excipients with known effect:
Sorbitol Liquid (non-crystallising)
Methyl parahydroxybenzoate
Propyl parahydroxbenzoate

For the full list of excipients, see section 6.1

#### **3 PHARMACEUTICAL FORM**

Oral suspension.

Product imported from Germany:
Off-white, banana flavoured, suspension

#### **4 CLINICAL PARTICULARS**

As per PA1077/084/005

## **5 PHARMACOLOGICAL PROPERTIES**

As per PA1077/084/005

## **6 PHARMACEUTICAL PARTICULARS**

# 6.1 List of excipients

sorbitol Liquid (non-crystallising) glycerol microcrystalline cellulose carmellose sodium vanillin banana flavour purified water methyl parahydroxybenzoate propyl parahydroxybenzoate

#### 6.2 Incompatibilities

Not applicable.

# 6.3 Shelf life

The shelf-life expiry date of this product is the date shown on the container and outer package of the product on the market in the country of origin.

Diluted: 4 weeks

29 April 2024 CRN00F70P Page 1 of 2

# **Health Products Regulatory Authority**

# **6.4 Special precautions for storage**

Do not store above 25°C.

#### 6.5 Nature and contents of container

62.5 mL amber glass bottle with white, child resistant cap containing a homogenous opaque white, viscous suspension having the taste and odour of banana. The pack contains 2 x 62.5 mL bottles and a double ended 5 mL and 2.5 mL/1.25 mL spoon.

# 6.6 Special precautions for disposal and other handling

For administration of 100 mg dose e.g. 2.5 mL of Zovirax 200 mg/5 mL Oral Suspension, use the measuring spoon provided or alternatively a graduated syringe.

## 7 PARALLEL PRODUCT AUTHORISATION HOLDER

IMED Healthcare Ltd.
Unit 625 Kilshane Avenue
Northwest Business Park
Ballycoolin
Dublin 15
Ireland

## **8 PARALLEL PRODUCT AUTHORISATION NUMBER**

PPA1463/199/003

## 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 26<sup>th</sup> April 2024

## 10 DATE OF REVISION OF THE TEXT

29 April 2024 CRN00F70P Page 2 of 2